Format

Send to

Choose Destination
Methods Mol Biol. 2016;1436:305-12. doi: 10.1007/978-1-4939-3667-0_20.

Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.

Author information

1
Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland.
2
Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.
3
Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
4
Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland. frbertoni@mac.com.
5
IOSI Oncology Institute of Southern Switzerland, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland. frbertoni@mac.com.

Abstract

To evaluate the antiproliferative activity of a novel BET Bromodomain inhibitor as single agent and in combination with the BTK inhibitor ibrutinib in non-Hodgkin lymphoma cell lines, we performed the MTT proliferation assay. This assay is based on the direct correlation between absorbance (measured colorimetrically at a wavelength of 570 nm) and cell proliferation. Thiazolyl Blue Tetrazolium Blue (MTT) is a yellowish solution that distinguishes between proliferating and dead cells since it is converted to water-insoluble MTT-formazan of dark blue color by mitochondrial dehydrogenases of living cells only.

KEYWORDS:

BET inhibitor; BRD inhibitor; Ibrutinib; Lymphoma; MTT

PMID:
27246223
DOI:
10.1007/978-1-4939-3667-0_20
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center